Corbus Pharmaceuticals announced positive results from their Phase 1/2 clinical study of CRB-701, showing an objective response rate of 47.6% in HNSCC, 37.5% in cervical cancer, and 55.6% in mUC. The study demonstrated a favorable safety profile, with no dose-limiting toxicities. Registrational studies are planned to start in mid-2026. The company will host an HNSCC KOL event during ESMO25 to discuss the data. CRB-701 is a next-generation ADC targeting Nectin-4, with Fast Track designations in HNSCC and cervical cancer. The FDA meeting is scheduled for this year to review the data before initiating registrational studies.

Read more at GlobeNewswire: Corbus Pharmaceuticals Presents CRB-701 Robust Clinical